RiverPark Advisors LLC Invests $129,000 in TransMedics Group, Inc. $TMDX

RiverPark Advisors LLC acquired a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 963 shares of the company’s stock, valued at approximately $129,000.

Other hedge funds have also recently bought and sold shares of the company. Opal Wealth Advisors LLC bought a new stake in shares of TransMedics Group in the second quarter valued at about $26,000. Smartleaf Asset Management LLC lifted its stake in TransMedics Group by 44.3% in the 1st quarter. Smartleaf Asset Management LLC now owns 440 shares of the company’s stock valued at $30,000 after acquiring an additional 135 shares in the last quarter. Quarry LP grew its stake in shares of TransMedics Group by 88.5% during the 1st quarter. Quarry LP now owns 592 shares of the company’s stock worth $40,000 after acquiring an additional 278 shares in the last quarter. Sound Income Strategies LLC bought a new stake in shares of TransMedics Group in the second quarter worth $48,000. Finally, CWM LLC lifted its position in shares of TransMedics Group by 20.1% in the first quarter. CWM LLC now owns 925 shares of the company’s stock worth $62,000 after purchasing an additional 155 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Edward M. Basile sold 4,142 shares of the company’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $130.45, for a total value of $540,323.90. Following the transaction, the director directly owned 2,866 shares in the company, valued at approximately $373,869.70. This represents a 59.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 7.00% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Needham & Company LLC reaffirmed a “buy” rating on shares of TransMedics Group in a research report on Thursday, October 30th. Wall Street Zen upgraded TransMedics Group from a “hold” rating to a “buy” rating in a report on Saturday, October 18th. Stifel Nicolaus assumed coverage on TransMedics Group in a research report on Thursday, September 4th. They issued a “hold” rating and a $115.00 target price on the stock. Jefferies Financial Group began coverage on TransMedics Group in a research note on Monday, October 13th. They issued a “buy” rating and a $145.00 price target for the company. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of TransMedics Group in a research note on Wednesday, October 8th. Seven equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, TransMedics Group has a consensus rating of “Moderate Buy” and an average target price of $131.80.

TransMedics Group Stock Up 4.1%

TMDX opened at $146.00 on Wednesday. The stock’s fifty day simple moving average is $121.19 and its 200 day simple moving average is $121.65. TransMedics Group, Inc. has a 1-year low of $55.00 and a 1-year high of $147.68. The stock has a market cap of $4.99 billion, a PE ratio of 59.11 and a beta of 2.05. The company has a current ratio of 7.69, a quick ratio of 7.13 and a debt-to-equity ratio of 1.43.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Wednesday, October 29th. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.29. The firm had revenue of $143.82 million for the quarter, compared to analysts’ expectations of $145.33 million. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. The business’s revenue was up 32.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.12 EPS. TransMedics Group has set its FY 2025 guidance at EPS. As a group, research analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.